Kangstem Biotech강스템바이오텍
217730 · KOSDAQ · ₩217730 · 강스템바이오텍
₩1,872▼ ₩27 (1.42%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩3.6B | ₩7.7B | ₩5.9B | ₩5.9B | ₩3.8B |
| Cost of sales | ₩2.7B | ₩3.4B | ₩3.4B | ₩3.4B | ₩2B |
| Gross profit | ₩845M | ₩4.3B | ₩2.5B | ₩2.5B | ₩1.8B |
| Operating income | −₩18B | −₩15B | −₩20B | −₩21B | −₩22B |
| Net income | −₩10B | −₩8B | −₩19B | −₩20B | −₩20B |
| Net income to shareholders | −₩10B | −₩8B | −₩19B | −₩20B | −₩20B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩81B | ₩56B | ₩71B | ₩69B | ₩90B |
| Current assets | ₩44B | ₩29B | ₩46B | ₩44B | ₩63B |
| Cash and equivalents | ₩2B | ₩2.8B | ₩5.5B | ₩3.9B | ₩6.7B |
| Total liabilities | ₩12B | ₩13B | ₩18B | ₩17B | ₩20B |
| Current liabilities | ₩8.3B | ₩7.7B | ₩8B | ₩5.1B | ₩6.8B |
| Borrowings | ₩7.7B | ₩6.7B | ₩5.6B | ₩5.6B | ₩5.8B |
| Total equity | ₩69B | ₩43B | ₩53B | ₩51B | ₩70B |
| Shareholders' equity | ₩69B | ₩43B | ₩53B | ₩51B | ₩70B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩12B | −₩19B | −₩17B | −₩18B | −₩16B |
| Capital spending | ₩661M | ₩593M | ₩1.3B | ₩368M | ₩3.4B |
| Free cash flow | −₩12B | −₩20B | −₩18B | −₩19B | −₩20B |
Consolidated where available. Amounts in won.
Also known as: Kangstem Biotech / 강스템바이오텍 / 217730 / KRX:217730
Source: KRX statistical information